GlassScriptPhysician profile
Andrew Willet
NPI 1922062884
$616.49
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $490 · 2020: $108 · 2022: $19.22.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $165.33 | 2019 | |
| Lilly USA, LLC | $77.30 | 2019-2020 | |
| Pfizer INC. | $62.83 | 2019-2020 | |
| Sanofi Pasteur INC. | $45.52 | 2019-2020 | |
| Shire North American Group INC | $37.98 | 2019 | |
| Astellas Pharma US INC | $36.12 | 2019 | |
| Merck Sharp & Dohme LLC | $34.86 | 2019-2020 | |
| Novo Nordisk INC | $28.78 | 2019 | |
| Amarin Pharma, INC. | $26.26 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.36 | 2019 | |
| Dexcom, INC. | $19.22 | 2022 | |
| Medtronic USA, INC. | $18.49 | 2019 | |
| Genentech USA, INC. | $15.32 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.05 | 2020 | |
| Seqirus USA INC | $12.07 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Willet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.